We Give Shareholders a Voice
Levi & Korsinsky announces the filing of a class action lawsuit in the United States District Court for the Southern District of California on behalf of Celladon Corporation (NASDAQGM: CLDN) shareholders who purchased shares between July 7, 2014 and June 25, 2015.
The complaint alleges that during the Class Period defendants’ made false and misleading statements and/or failed to disclose adverse information regarding the Company’s prospects for its lead drug candidate, MYDICAR, for treating enzyme deficiency in heart failure patients that results in inadequate pumping of the heart. On April 26, 2015, Celladon announced that the Company’s Phase 2b CUPID2 trial of MYDICAR did not meet its primary and secondary goals. Then on June 1, 2015, Celladon issued a press release announcing the abrupt resignation of the Company’s Chief Executive Officer. Then, on June 26, 2015, Celladon announced the suspension of its plans for further research or development of its MYDICAR program and other pre-clinical programs, indicating there was a possibility that the Company could be liquidated with net cash available to shareholders of $25-$30 million. If you suffered a loss in Celladon you have until August 31, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.